

## Degenerative diseases of the CNS: Quantitative Neuroimaging

**Dr. Vasileios K. Katsaros, MD, PhD**


- Department of Advanced Imaging Modalities, CT and MRI, General Anti-Cancer and Oncological Hospital "St. Savvas",
- Department of Neurosurgery, University of Athens - Greece

## Quantitative Neuroimaging - Biomarkers: Do we need all this information ?

Why ???

↓

Personalized  
(Precision)  
Medicine



## DEMENTIA

- Incidence
  - 44 Million Worldwide
  - 850 Thousand people in the UK
  - 38% of the population has a family member or close friend with dementia
- Cost
  - £360 billion worldwide
  - £23 billion UK



## DIADeM Clinical Report

PATIENT INFORMATION & GLOBAL ANALYSIS

Name	Year of Birth	Gender	Scan Date
Joanna Miller	1932	Female	12/01/2008


### HIPPOCAMPAL VOLUME

Volume (ml) and percentile (pctl)

Left	Right
11.02 ml 1.8 pctl	11.24 ml 1.1 pctl

### BRAIN VOLUME

% of total intracranial volume



### QUALITY CONTROL

assessment score

Metric	Type	Score	Status
SNR	GM	18.2	Pass
	WM	20.1	Pass
CNR	WM/GM	2.4	Pass
	GM/CSF	1.8	Caution
Acquisition	Movement	0.2	Pass
	Heating	0	Pass
	RF band Coverage	100%	Pass
Processing	Masks fit	2.2x10 <sup>6</sup>	Pass
	Reformat	1.4 s	Pass

**Degenerative Diseases of CNS – Dementias Classification**

**Dementias**


- Alzheimer's disease (62%)
- Vascular dementia (17%)
- Mixed dementia (10%)
- Lewy's body dementia (4%)
- Other rare causes of dementia (3%)
- Frontotemporal dementia (2%)

➤ Corticobasal degeneration



➤ Creutzfeld-Jakob's disease

➤ Multiple Sclerosis

➤ Parkinson's disease dementia



**Alzheimer's Disease Diagnosis: amyloid-PET**

Stereotactic Surface Projection (SSP)

Figure 2. 102111 Using Positron Emission Tomography and 1-Fluoro-2-Deoxy-2-Fluoro-D-Glucose to Measure Amyloid in Patients With Mild Cognitive Impairment or Dementia Due to Alzheimer's Disease. *Archives of Neurology*, 68 (11), 1400-1411.

**Role of Quantitative Neuroimaging in the Evaluation of Alzheimer's Disease**

- ❖ MRI-based measurements of *brain atrophy* are regarded as **valid neuroimaging biomarkers** of the state and progression of Alzheimer's disease.
- ❖ Rates of **whole-brain atrophy** have been estimated at **1.4–2.2% per year** in Alzheimer patients, whereas the rates of atrophy during **normal aging** usually do not exceed **0.7% per year**.
- ❖ This atrophy can be quantified, by **automated segmentation** of the brain parenchyma.


**Role of Quantitative Neuroimaging in the Evaluation of Alzheimer's Disease**

- ❖ **Atrophy of the hippocampus** is also a valid biomarker of mild cognitive impairment (MCI) and Alzheimer's disease progression.
- ❖ The rate of atrophy varies from **3 to 6% per year** in Alzheimer's disease, whereas it is limited to **0.3–2.2% per year** in normal aging.
- ❖ Although visual rating scales or the manual outlining of the hippocampus can be used, **automated software programs**, reduce the **interaction time and increase the reliability** of the measurement.
- ❖ A **harmonized protocol for hippocampal volumetry** has been defined in order to reduce the variability between the studies.



MRI Report including volumetry

80-years-old female



There is volume loss (also qualitatively demonstrated) of the **whole brain**, especially of the temporal regions and the **hippocampi**, mainly the left, which are **beneath (<5%)** taking into account the gender and age of the patient, in combination with significant dilatation of the **inferior (temporal) horns** of the lateral ventricles (**>95%**), findings which are consistent with **Alzheimer's disease**.

Measurement	Value	Normal Range	Comment
Whole Brain	3.58	0.26 (2.44-4.05)	< 5
Lateral Ventricles	57.04	4.28 (1.35-4.74)	> 95
Inferior Lateral Ventricles	6.25	0.43 (0.13-0.35)	> 95

### Biomarkers for Clinical Evaluation of patients with Mild Cognitive Impairment (MCI)

A number of biomarkers have been developed that indicate the presence of Alzheimer's disease (AD) pathology and AD-associated neuronal injury in vivo. These biomarkers have strong potential for clinical use in etiological determination, predictive prognosis, monitoring disease progression, and for serving as outcome measures in clinical trials of potential disease-modifying therapies.

**Biomarkers of brain amyloid pathology: amyloid imaging**

- The first amyloid-sensitive radiotracer to be developed, Pittsburgh compound B binds to metabolite fibrillary amyloid in the brain, a major constituent of the amyloid plaques that are one of the hallmark pathological features of AD (i). Pittsburgh compound B is used widely in research studies but has limited clinical potential since its short half-life restricts its availability to clinics with a cyclotron on site. More recently developed <sup>11</sup>C-labeled tracers, flutemetamol, florbetaben and florbetapir, show similar high affinity for fibrillary amyloid, but have longer half-lives, allowing for central production and distribution, rendering them more amenable to widespread clinical use (i). Florbetaben has recently received approval for clinical use by the US FDA to indicate presence of amyloid in the brain.

**Cerebrospinal Fluid (CSF) levels**

- Cerebrospinal fluid (CSF) levels of Aβ<sub>42</sub>, the major constituent of amyloid plaques can be obtained from lumbar puncture. CSF Aβ<sub>42</sub> levels decrease as plaque levels increase, suggesting that Aβ<sub>42</sub> becomes sequestered in plaques, leaving less to diffuse into the CSF (ii). Decreased CSF Aβ<sub>42</sub> levels can therefore indicate presence of amyloid plaques in the brain.

**Biomarkers of neuronal injury: CSF tau & phosphorylated tau levels**

- Elevated levels of tau in the CSF are a nonspecific reflection of neuronal injury. Phosphorylated tau is a more specific reflection of the phosphorylated state of tau, and reflects neurofibrillary tangle formation in the brain (iii); levels of both are increased in AD. The ratio of CSF tau or phosphorylated tau to CSF Aβ<sub>42</sub> shows greater sensitivity to AD than any single CSF measure (iii). Commercial CSF analysis services (e.g., Athena Diagnostics, MA, USA) can indicate whether CSF biomarker levels are consistent with AD.


**Volumetric MRI**

- AD is associated with widespread brain atrophy, even in prodromal stages, with prominent involvement of the hippocampus, a medial temporal lobe structure important for memory (iv). The presence of atrophy in medial temporal structures, which can be visually rated or more precisely quantified using FDA-approved automated medical device image analysis software (e.g., NeuroQuant<sup>®</sup>, CorTechs Labs, Inc., CA, USA), is associated with a high risk of imminent decline to dementia (iv).

**Fluorodeoxyglucose (FDG)-PET**

- Specific dysfunction: neuronal injury and neuron loss leads to hypometabolism in parietal and temporal areas detectable with FDG-PET (v). FDG-PET is currently approved for clinical use to distinguish AD from frontotemporal dementia, which is characterized by hypometabolism in frontal rather than in posterior brain regions.



### Frontotemporal Dementia (Pick's Disease)



Case Courtesy by Dr. S. Bidas, UCLH, London, UK and Siemens, Lausanne, CH

### Role of Quantitative Neuroimaging in the Evaluation of Multiple Sclerosis

- Automated volumetric MR imaging offers an opportunity to extend brain atrophy measurements to the routine management of Multiple Sclerosis (MS) patients by showing regional and whole brain atrophy, which can be monitored over time.
- In MS patients, brain volume loss, specifically of the **cerebral cortex and thalamus**, has been correlated with disability progression and cognitive impairment.
- According to several studies, **brain volume loss** is an **applicable measure** of widespread central nervous system damage leading to clinical disease progression, and serves as a **useful outcome in evaluating MS therapies**.




- ### What else do we need in quantification of MS ?
- ❖ Measures/Volumes of lesion load
    - FLAIR hyperintensities
    - T1-W (before Gadolinium) “black holes”
    - Enhancing lesions
  - ❖ New lesions
  - ❖ Enlarging lesions
  - ❖ Monitoring in order to
    - define the dissemination of the disease in space and time
    - treatment control

### MRI in MS

**Radiological report:**  
 Supratentorial, there are **many** T2-hyperintense lesions from the subcortical to the deep periventricular white matter in both hemispheres. Multiple lesions run perpendicular to the lateral ventricles. **Moderate** global cortical atrophy. No Gd enhancing lesions were seen.

Courtesy by Wim van Hecke, Icometrix, Belgium



### Multiple Sclerosis initial presentation

**Radiological report including Volumetry:**

Supratentorial, there are several T2-hyperintense lesions from the subcortical to the deep periventricular white matter in both hemispheres, with a total volume in FLAIR sequence of 6.9 ml. The volume of white matter hypointensities ("black holes") in T1W images was measured 3.08 ml and the volume of enhancing lesions 0.5 ml. Multiple lesions run perpendicular to the lateral ventricles. The total brain volume was measured 1465 ml, indicating globalized atrophy, while gray matter volume (938 ml) is within normal range according to patient's age.

Structure	Type	Value	Unit
White Matter	WM	10.02	ml
Caudate white matter	WM	11.02	ml
Corpus callosum anterior part	WM	0.87	ml
NA	NA	0.54	ml
HA	HA	0.37	ml
LA	LA	0.23	ml
RA	RA	0.47	ml
LA	LA	0.23	ml
RA	RA	0.47	ml
Brain Volume	Brain	1465	ml
Gray Matter	GM	938	ml
White Matter	WM	527	ml
CSF	CSF	920	ml


### Quantitative - Volumetric Methods

- 3D - T1 - MPRAGE (ADNI protocol) (for MS + i.v. Gad)
- 3D - FLAIR (for MS)
- 3D - T2 W (optional)
- 3D - SWI (optional)
- fMRI (BOLD - optional)
- Diffusion (DTI - optional)
- Perfusion MRI (optional)
- Spectroscopy
- PET or hybrid PET-MRI (if available)

**Segmentation Methods may be grouped as:**

- intensity-based methods (including thresholding, region growing, classification, and clustering)
- atlas-based methods For Biomedical Engineers, PhD etc
- surface-based methods (including active contours and surfaces, and multiphase active contours)
- manual segmentation
- hybrid segmentation methods

Computational and Mathematical Methods in Medicine 2015



**Segmentation Methods** For Medical Doctors

- Fully Automated Segmentation
- Semi-Automatic Segmentation
- Manual Segmentation



Computational and Mathematical Methods in Medicine 2015

**Fully Automated Segmentation - Open Source**

- **FreeSurfer** - Athinoula Martinos Center for Biomedical Imaging by the Laboratory for Computational Neuroimaging, Boston, USA
- **FSL** - Analysis Group, FMRIB, Oxford, UK
- **volBrain** - IBIME, UPV, Spain and LaBRI UMR 5800, Université de Bordeaux, CNRS, France


Computational and Mathematical Methods in Medicine 2015





### Fully Automated Segmentation - CE/FDA


- BrainMagix - Imagilys, Brussels, Belgium
- Neuroquant - CorTechs Labs, San Diego, USA
- Msmatrix - Icometrix, Leuven, Belgium




**Comparison of FreeSurfer, FSL and manual segmentation**

- Compared to hand tracing, a 3-D shape analysis of the **hippocampus** showed **FreeSurfer** was more accurate than FIRST, particularly in the head and tail.
- However, **FSL/FIRST** more accurately represented the **amygdala** shape than FreeSurfer, which inflated its anterior and posterior surfaces.
- **Comment:** The newer version of FreeSurfer resolves the amygdala inflation


Neuroimage, 2009 April 15; 45(3): 855-866.





### Semi-Automatic Segmentation

- **BrainMagix/CE** - Imagilys, Brussels, Belgium
- **itk-SNAP/Open Source**, University of Pennsylvania and University of Utah, USA



### Discussion (extreme case) - Caution Automated vs Manual Segmentation

**Total Lesion Burden : 6 cm<sup>3</sup>**

**Manual Segmentation - Open Source**

- FreeSurfer - Athinoula Martinos Center for Biomedical Imaging by the Laboratory for Computational Neuroimaging, Boston, USA
- FSL - Analysis Group, FMRIB, Oxford, UK
- Osirix, Pixmeo S.A.R.L., Bernex, Switzerland (*Osirix MD with FDA approval*)
- itk-SNAP, University of Pennsylvania and University of Utah, USA
- ImageJ, The Laboratory for Optical and Computational Instrumentation, University of Wisconsin-Madison, USA

II. Amygdala

**Osirix MD**

Right Hippocampus	Left Hippocampus
1.000 cm <sup>3</sup>	1.000 cm <sup>3</sup>

**itk-SNAP Alzheimer's**

Label Name	Voxel Count	Volume (mm <sup>3</sup> )	Intensity Mean ± SD (μ, mm <sup>3</sup> , Spd=8000)
Right Hippocampus	3565	3565	185.6782±24.3957
Left Hippocampus	3311	3311	187.8666±24.7322




ΑΓΙΟΣ ΣΑΒΒΑΣ  
ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΚΕΝΤΡΟ  
ΠΑΡΕΧΟΥΣ ΥΠΗΡΕΣΙΩΝ

ΠΑΤΡΙΚΗΣ ΧΩΑΗ  
ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΚΕΝΤΡΟ  
ΠΑΡΕΧΟΥΣ ΥΠΗΡΕΣΙΩΝ

UNIVERSITÄT  
KLINIKUM  
TÜBINGEN

**Full Automated to Manual Segmentation – Research only**

- **Brain Voyager**, Brain Innovation B.V. Maastricht  
The Netherlands



ΑΓΙΟΣ ΣΑΒΒΑΣ  
ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΚΕΝΤΡΟ  
ΠΑΡΕΧΟΥΣ ΥΠΗΡΕΣΙΩΝ

ΠΑΤΡΙΚΗΣ ΧΩΑΗ  
ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΚΕΝΤΡΟ  
ΠΑΡΕΧΟΥΣ ΥΠΗΡΕΣΙΩΝ

UNIVERSITÄT  
KLINIKUM  
TÜBINGEN

**Case presentation**


ΑΓΙΟΣ ΣΑΒΒΑΣ  
ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΚΕΝΤΡΟ  
ΠΑΡΕΧΟΥΣ ΥΠΗΡΕΣΙΩΝ

ΠΑΤΡΙΚΗΣ ΧΩΑΗ  
ΕΠΙΧΕΙΡΗΣΙΑΚΟ ΚΕΝΤΡΟ  
ΠΑΡΕΧΟΥΣ ΥΠΗΡΕΣΙΩΝ


UNIVERSITÄT  
KLINIKUM  
TÜBINGEN

**Normative Curves PDF**

Based on a Database of 1770 subjects, normal and patients







**Primary Progressive Aphasia, Non-Fluent Variant**



CENTRAL CLINIC OF ATHENS  
RESEARCH & TREATMENT MEDICAL CENTER

**BrainMagix**






Logos: ΑΓΙΟΣ ΓΑΒΡΑΗΛ, ΙΑΤΡΙΚΗΣ ΣΧΟΛΗΣ ΕΠΙΘΕΩΡΗΣΗ ΚΑΙ ΠΡΟΓΝΩΣΤΙΚΟ ΠΕΡΙΣΤΡΩΦΟ ΑΠΟ ΠΑΘΟΛΟΓΟΥ ΑΛΤΕΡΗΣΙΑΣ, UNIVERSITÄTSSCHULE KLINIKUM GIESSEN

**Structural/Functional Connectivity of Dementia**


**Primary Progressive Aphasia, Non-Fluent Variant**

**PDF**

## Parkinson's disease with Initial Presentation as Primary Freezing of Gait



## Parkinson's disease with Initial Presentation as Primary Freezing of Gait



Prohilaric tractography displayed on the MNI152 standard brain. (a) Axial section through the upper pons and cerebellum. In FOG patients (red) connectivity with the cerebellum is absent, whereas non FOG PD patients show similar connectivity to control subjects. (b) Axial section through the mid-pons and cerebellum. FOG patients (red) showed anterior pontine connectivity (arrow) which was absent in non FOG PD patients and controls.

**Connectivity of the pedunculopontine nucleus in parkinsonian freezing of gait**  
 Patrick M. Schwedor<sup>1</sup>, Peter C. Haindl<sup>1</sup>, Alex L. Green<sup>2</sup>, Gerardus Quaghebeur<sup>3</sup>, John Smit<sup>4</sup> and Tjoo Z. Ass<sup>5</sup>


NeuroReport 2015, 26:16-21

## Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy


Jörg B. Schulz, MD,\* Martin Stalaj, MD,† Dirk Wodtkind,\* Andrea R. Lufi,† Michael Abele, MD,\* Karsten Voigt, MD,† Johannes Dichgans, MD,\* and Thomas Klöckner, MD\*

By using three-dimensional magnetic resonance imaging-based volumetry, we studied atrophy of the caudate nucleus, putamen, brainstem, and cerebellum in patients with idiopathic Parkinson's syndrome (IPS, n = 11), progressive supranuclear palsy (PSP, n = 6), and multiple system atrophy with predominant parkinsonism (MSA-P, n = 12) or ataxia (MSA-C, n = 17). Patients were compared with a total of 46 controls, of whom 16 were age-matched. Mean striatal, cerebellar, and brainstem volumes were normal in patients with IPS. We found significant reductions in mean striatal and brainstem volumes in patients with MSA-P, MSA-C, and PSP, whereas patients with MSA-C and MSA-P also showed a reduction in cerebellar volume. On an individual basis, volumes of structures in patients with MSA and PSP showed an extensive overlap with the normal range with the exception of brainstem volumes in patients with MSA-C. Therefore, groups could not be discriminated on the basis of individual structure volumetry. Application of support discriminant analysis, however, allowed discrimination of all 12 patients with MSA-P, 15 of 17 patients with MSA-C, and 5 of 6 patients with PSP from the normal and IPS cohorts. However, patients with IPS could not be separated from controls and patients with MSA-P could not be separated from patients with PSP. In conclusion, total intracranial volume-normalized magnetic resonance imaging-based volumetric measurements provide a sensitive marker to discriminate typical and atypical parkinsonism.

Schulz JB, Stalaj M, Wodtkind D, Lufi AR, Abele M, Voigt K, Dichgans J, Klöckner T. Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Ann Neurol 1999;45:65-74



**Fig 1. Region growing-based segmentation of the cerebellum and brainstem.** On the midaxial (top panels) and parasagittal (bottom panels) sections on the left side, a nonoverlapping segmented cerebellum is shown. The four images on the right side display a segmented brainstem from medial (top middle) to lateral (bottom right) position. The brainstem is presegmented by using four planes (black) that are orthogonal to the sagittal plane. Each plane is adjusted for two landmarks (superior: mammillary body, posterior commissure, displaced downwards for one-third of the height of the midbrain; inferior: posterior rim of the foramen magnum, parallel to the superior plane; posterior: posterior commissure, obex, displaced backward as far as the inferior colliculus; anterior plane was required by the software but is not needed to separate the brainstem from the cerebrospinal fluid. Therefore, anterior delineation was done by region growing). Subsequently, the region growing algorithm is able to define the exact outline of the brainstem in three dimensions. The segmented brainstem is then subtracted from the original images, resulting in a blackened area (images on the left). Subtraction avoided overlap between the volumes of brainstem and cerebellum. (Sequence type: three-dimensional, fast low-angle shot (FLASH); TE/TR = 5 msec/15 msec; slice thickness = 0.9 mm; resolution = 0.9 × 0.9 mm<sup>2</sup>.)



**NeuroImage**  
www.elsevier.com/locate/yimg  
Available online 12 October 2013

**Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration**

Klaus Gellera<sup>1,\*</sup>, Till-Karsten Haene<sup>2,3</sup>, Andrea Luft<sup>4,5</sup>, Nicholas Patronas,<sup>6</sup> Johannes Dichgans,<sup>1,2</sup> René Litvan,<sup>7</sup> and Jörg B. Schulz<sup>1,2,4,8</sup>

<sup>1</sup>Department of Neurology, University of Göttingen, Göttingen, Germany; <sup>2</sup>Department of Neurology, University of Würzburg, Würzburg, Germany; <sup>3</sup>German Center for Neurodegenerative Diseases, Göttingen, Germany; <sup>4</sup>Department of Psychiatry, University of Göttingen, Göttingen, Germany; <sup>5</sup>Department of Psychiatry, University of Göttingen, Göttingen, Germany; <sup>6</sup>Department of Neurology, University of Göttingen, Göttingen, Germany; <sup>7</sup>Department of Neurology, University of Göttingen, Göttingen, Germany; <sup>8</sup>Department of Neurology, University of Göttingen, Göttingen, Germany


Received 4 July 2013; revised 6 September 2013; accepted 20 September 2013

Imaging criteria may complement clinical criteria to differentiate Parkinsonian syndromes. MRI-based volumetry supports a correct diagnosis of akinetic-rigid Parkinsonian syndromes during lifetime. We extend here our previous report by showing that not only idiopathic Parkinson's disease can be separated from MSA and PSP (Schulz et al., 1999), but also PSP from CBD based on MRI-volumetry. Although there are genetic and biochemical similarities between PSP and CBD, our results argue in favor of separate disease entities. Replication in other centers and prospective studies will show whether the procedures described here will have clinical applicability.

**Structural/Functional Connectivity**

**Multiple Sclerosis**

**PDF**



**Comparing manual and automatic segmentation of hippocampal volumes: reliability and validity issues in younger and older brains.**

Wenger E<sup>1</sup>, Mårtensson J, Noack H, Bodammer NC, Kühn S, Schaefer S, Heinze HJ, Düzel E, Bäckman L, Lindenberger U, Lovden M.

**Author information**  
<sup>1</sup>Center for Lifespan Psychology, Max Planck Institute for Human Development, Germany.

**Abstract**  
We compared hippocampal volume measures obtained by manual tracing to automatic segmentation with FreeSurfer in 44 younger (20–30 years) and 47 older (60–70 years) adults, each measured with magnetic resonance imaging (MRI) over three successive time points, separated by four months. Retest correlations over time were very high for both manual and FreeSurfer segmentations. With FreeSurfer, correlations over time were significantly lower in the older than in the younger age group, which was not the case with manual segmentation. Pearson correlations between manual and FreeSurfer estimates were sufficiently high, numerically even higher in the younger group, whereas intra-class correlation coefficient (ICC) estimates were lower in the younger than in the older group. FreeSurfer yielded higher volume estimates than manual segmentation, particularly in the younger age group. Importantly, FreeSurfer consistently overestimated hippocampal volumes independently of manually assessed volume in the younger age group, but overestimated larger volumes in the older age group to a less extent, introducing a systematic age bias in the data. Age differences in hippocampal volumes were significant with FreeSurfer, but not with manual tracing. Manual tracing resulted in a significant difference between left and right hippocampus (right > left), whereas this asymmetry effect was considerably smaller with FreeSurfer estimates. We conclude that FreeSurfer constitutes a reasonable method to assess differences in hippocampal volume in young adults. FreeSurfer estimates in older age groups should, however, be interpreted with care until the automatic segmentation pipeline has been further optimized to increase validity and reliability in this age group.

**Personalized (Precision) Medicine** ✓

*Thank you*



*... for your Attention*





### References for QNI of Alzheimer's disease

- Frisoni et al. The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 2010, 6:67–77.
- Frisoni & Jack. Harmonization of magnetic resonance-based manual hippocampal segmentation: a mandatory step for wide clinical use. Alzheimers Dement. 2011, 7:171-174.
- \**Hermoye, Katsaros* et al. Quantitative Imaging Biomarker Software for Neurological Disorders. RSNA, Chicago 2014.



### References for QNI of Multiple Sclerosis

- Radue, EW, et al. (2013). Brain Atrophy: An in-vivo Measure of Disease Activity in Multiple Sclerosis. Swiss Medical Weekly. 143: w13887.
- Sormani MP, Arnold DL, De Stefano N. (2014). Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Disability in Multiple Sclerosis. Ann Neurol. 75:43-49.
- Kalincik T, et al. (2012). Volumetric MRI Markers and Predictors of disease Activity in early Multiple Sclerosis: A Longitudinal Cohort Study. PLoS ONE 7(11): e50101